Prostate Cancer, Hereditary, 5

Watchlist

(log in to enable)

Retrieved

2019-09-22

Source

Omim

Trials

—

Genes

RNASEL, HOXB13, ELAC2, MSR1, CHEK2, BRCA2, BRCA1, CDKN1B, MSMB, SRD5A2, CDH1, EPHB2, NBN, TTC28, LARP4B, KDM2A, BCL2L11, TSHZ1, HAUS6, DENND4B, ADGRG1, MBD2, BCAS1, PPFIBP2, TCF7L2, HNF1B, TCF4, B3GAT1, MAD1L1, UHRF1BP1, COL23A1, RN7SKP114, RNU6-491P, RNU6-148P, THEG5, MEIS1-AS3, OACYLP, DUBR, RASSF3, CDCA7, RNF43, MOB2, ATAT1, SUGCT, RFX7, PKNOX2, FBRSL1, KNL1, RNLS, EMSY, RNU6-456P, DOCK2, PAX9, MYO9B, MMP14, POU2F2, MBNL1, MAP2K1, ITGB8, INCENP, CHD3, HLA-DOA, DNMT3B, MECOM, CASP8, BCL2, ATM, ARHGAP6, TOR1A, KLK3, PCAP, CBX4, HPCX, AMACR, KLF6, AR, HPC3, CYP17A1, MYC, NPEPPS, PROS1, PSAT1, PLAG1, GSTK1, CYP19A1, RGS8, BRIP1, SLCO6A1, MIR888, ARL11, CYP1B1, CYP1A1, RGSL1, SULT1A1, PALB2, ERG, RASA1, PTEN, TP53, VDR, SPOP, PPM1D, PPP2R2A, PON1, PKHD1, LZTS1, MLH1, LGALS8, KLK2, RASA2, PINX1, GSTT1, PDSS2, GSTP1, GSTM1, CT55

Drugs

Mitoxantrone ( NOVANTRONE )

Interested in hearing about new therapies?

For a general discussion of hereditary prostate cancer, see 176807.

Mapping

Rokman et al. (2005) performed linkage analysis using 17 fine-mapping markers in 16 multiplex Finnish families with hereditary prostate cancer and found evidence for linkage at 3p26, with a multipoint heterogeneity adjusted lod of 3.39. The highest lod scores were around markers D3S1270 and D3S4559 (alpha = 0.89), narrowing the peak region to approximately 2 cM. Rokman et al. (2005) concluded that 3p26 is likely to contain a predisposing gene for Finnish hereditary prostate cancer, although no disease-segregating variants were found in 2 candidate genes in the region.